Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifeline extended: HIV-Positive kids get crucial drug after study ends

NCT ID NCT03016533

Completed Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

Summary

This study provided continued access to the HIV medication dolutegravir for children and adolescents who had successfully completed earlier clinical trials. It aimed to ensure these young patients could keep receiving their effective treatment until the drug became commercially available in their country. The study monitored the safety of the medication and how well it continued to control the virus over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Los Angeles, California, 90095, United States

  • GSK Investigational Site

    Fort Lauderdale, Florida, 33316, United States

  • GSK Investigational Site

    Memphis, Tennessee, 38105-3678, United States

  • GSK Investigational Site

    Gaborone, Botswana

  • GSK Investigational Site

    Belo Horizonte, 30130-100, Brazil

  • GSK Investigational Site

    Nova Iguaçu, 26030-380, Brazil

  • GSK Investigational Site

    RibeirAo PretoSP, 14048-900, Brazil

  • GSK Investigational Site

    Rio de Janeiro, 21941-612, Brazil

  • GSK Investigational Site

    Cape Town, 7505, South Africa

  • GSK Investigational Site

    Johannesburg, 2001, South Africa

  • GSK Investigational Site

    Soweto, 1862, South Africa

  • GSK Investigational Site

    Umlazi, 4066, South Africa

  • GSK Investigational Site

    Moshi, 3010, Tanzania

  • GSK Investigational Site

    Bangkok, 10700, Thailand

  • GSK Investigational Site

    Chiang Mai, 50200, Thailand

  • GSK Investigational Site

    Chiang Rai, 57000, Thailand

  • GSK Investigational Site

    Harare, Zimbabwe

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS